PriceTargets.com logo

Kalaris Therapeutics - KLRS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 94.26%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$5.92 As of 12/4/2025 05:00 PM ET
▲ +0.38 (6.86%)

This chart shows the closing price for KLRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kalaris Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KLRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KLRS

Analyst Price Target is $11.50
▲ +94.26% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Kalaris Therapeutics in the last 3 months. The average price target is $11.50, with a high forecast of $20.00 and a low forecast of $3.00. The average price target represents a 94.26% upside from the last price of $5.92.

This chart shows the closing price for KLRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 polled investment analysts is to moderate buy stock in Kalaris Therapeutics. This rating has held steady since October 2025, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/3/2025CitigroupInitiated CoverageOutperform
11/3/2025Citizens JmpInitiated CoverageMarket Outperform$20.00
10/8/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
9/27/2025Weiss RatingsReiterated RatingSell (E) ➝ Sell (E)
9/2/2025Raymond James FinancialInitiated CoverageStrong-Buy
7/23/2025Piper SandlerSet TargetNeutral$3.00
7/23/2025Piper SandlerInitiated CoverageNeutral$3.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Kalaris Therapeutics logo
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $5.92
Low: $5.33
High: $6.00

50 Day Range

MA: $5.56
Low: $4.38
High: $8.03

52 Week Range

Now: $5.92
Low: $2.14
High: $12.90

Volume

210,203 shs

Average Volume

160,544 shs

Market Capitalization

$110.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kalaris Therapeutics?

The following sell-side analysts have issued stock ratings on Kalaris Therapeutics in the last twelve months: Citigroup Inc., Citizens Jmp, Piper Sandler, Raymond James Financial, Inc., Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for KLRS.

What is the current price target for Kalaris Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Kalaris Therapeutics in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 94.3%. Citizens Jmp has the highest price target set, predicting KLRS will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $3.00 for Kalaris Therapeutics in the next year.
View the latest price targets for KLRS.

What is the current consensus analyst rating for Kalaris Therapeutics?

Kalaris Therapeutics currently has 1 sell rating, 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KLRS.

What other companies compete with Kalaris Therapeutics?

Other companies that are similar to Kalaris Therapeutics include Evolus, SNDL, LB Pharmaceuticals, PepGen and Siga Technologies. Learn More about companies similar to Kalaris Therapeutics.

How do I contact Kalaris Therapeutics' investor relations team?

Kalaris Therapeutics' physical mailing address is 1100 WINTER STREET, WALTHAM, MA, 02451. The company's listed phone number is (617) 433-2605 and its investor relations email address is [email protected]. The official website for Kalaris Therapeutics is allovir.com. Learn More about contacing Kalaris Therapeutics investor relations.